<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pustular psoriasis: Management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pustular psoriasis: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pustular psoriasis: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert E Kalb, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristina Callis Duffin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H167786942"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pustular psoriasis is an uncommon subtype of psoriasis that may present as a generalized pustular skin eruption (generalized pustular psoriasis [GPP]) or a localized pustular skin eruption (acrodermatitis continua of Hallopeau and palmoplantar pustulosis)  (<a class="graphic graphic_picture graphicRef94789 graphicRef94790 graphicRef95194" href="/z/d/graphic/94789.html" rel="external">picture 1A-C</a>). The goals of treatment of GPP are to improve skin manifestations, to alleviate associated systemic symptoms, and to minimize risk for life-threatening systemic complications. Treatment of localized pustular psoriasis is indicated to minimize the development of bothersome or disabling symptoms.</p><p>The treatment of GPP and localized pustular psoriasis will be reviewed here. The clinical features of pustular psoriasis, the management of pustular psoriasis in pregnant women (impetigo herpetiformis), and the management of other forms of psoriasis are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">"Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5564.html" rel="external">"Dermatoses of pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/112983.html" rel="external">"Psoriasis in children: Management of chronic plaque psoriasis"</a> and  <a class="medical medical_review" href="/z/d/html/15280.html" rel="external">"Guttate psoriasis"</a>.)</p><p class="headingAnchor" id="H167786956"><span class="h1">GENERALIZED PUSTULAR PSORIASIS</span></p><p class="headingAnchor" id="H1196879757"><span class="h2">Disease overview</span><span class="headingEndMark"> — </span>Generalized pustular psoriasis (GPP) is characterized by the development of a widespread eruption of pustules and erythematous plaques  (<a class="graphic graphic_picture graphicRef94789 graphicRef94790 graphicRef95194" href="/z/d/graphic/94789.html" rel="external">picture 1A-C</a>). A preceding history of psoriasis may or may not be present. The acute variant (also known as generalized pustular psoriasis of von Zumbusch) is characterized by the sudden onset of a pustular eruption accompanied by fever and malaise. Laboratory abnormalities, such as leukocytosis, an elevated erythrocyte sedimentation rate, hypocalcemia and other electrolyte abnormalities, hypoalbuminemia, and elevated liver enzymes, are common. In addition, serious complications, including sepsis and hepatic, respiratory, or renal dysfunction, can occur [<a href="#rid1">1-4</a>]. (See  <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">"Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Generalized pustular psoriasis'</a>.)</p><p>GPP may also present as a less acute disorder in which patients develop widespread, annular or figurate, erythematous plaques with peripheral pustules and scale (generalized annular pustular psoriasis) [<a href="#rid4">4,5</a>]. Pain and fever may accompany these cutaneous manifestations. Generalized annular pustular psoriasis is a common presentation of pustular psoriasis in children. (See  <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">"Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">"Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Epidemiology'</a>.)</p><p>There is no cure for GPP, and recurrences are common [<a href="#rid4">4</a>]. Thus, long-term treatment is often required to minimize recurrences of disease.</p><p class="headingAnchor" id="H167785525"><span class="h2">Approach to therapy</span><span class="headingEndMark"> — </span>Determining the optimal approach to treatment is complicated by the lack of high-quality data on the efficacy of treatments for GPP. Data on treatment primarily consist of retrospective studies, case reports, and expert opinion, with most studies originating from a single country (Japan). Interpretation of the available data is further compromised by the lack of a validated grading system for the severity of GPP, and the absence of a standardized method of assessing the response to treatment [<a href="#rid6">6</a>].</p><p>The approach described in this topic reflects our preferred approach based upon review of the literature and clinical experience; other approaches may also be reasonable. In Japan, multiple therapies are approved for the treatment of GPP. Regulatory bodies in the United States and European Union have not approved any therapies for GPP.</p><p>The treatment approach reviewed below focuses on nonpregnant adults with GPP. The treatment of GPP in pregnant women and children is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5564.html" rel="external">"Dermatoses of pregnancy", section on 'Pustular psoriasis of pregnancy'</a> and <a class="local">'Children'</a> below.)</p><p>Increasing knowledge about the pathogenesis of GPP associated with <em>IL36RN</em> mutations may lead to new therapeutic options for this form of GPP. (See <a class="local">'IL36RN mutations'</a> below and  <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">"Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Genetics'</a>.)</p><p class="headingAnchor" id="H1973476139"><span class="h3">Important interventions</span><span class="headingEndMark"> — </span>Our approach to treatment consists of the following key steps:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Determine need for hospitalization and supportive care </strong>– Patients with acute GPP usually appear systemically ill, and admission to the hospital often is necessary to ensure adequate supportive care. The decision to hospitalize a patient is made based upon global consideration of the severity of illness, vital sign stability, fluid and electrolyte status, and concern for systemic infection.</p><p></p><p class="bulletIndent1">Supportive skin care measures may help to soothe skin symptoms in patients with GPP. Use of moisturizers, wet wraps, and/or oatmeal baths can be beneficial in patients with this disease [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identify and discontinue the causative drug (in drug-induced cases) </strong>– The withdrawal or administration of a variety of drugs has been linked to the development of GPP. In general, the causative agent should be discontinued, provided this can be done safely. There is at least one report of successful management of GPP without discontinuation of the inciting medication [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1">Systemic glucocorticoids are commonly cited contributors [<a href="#rid4">4</a>]. However, there is insufficient evidence to confirm the best way to discontinue systemic glucocorticoids in patients with glucocorticoid-induced GPP. Options include maintaining the glucocorticoid dose until disease control is achieved with other therapies and continuing to taper the systemic glucocorticoid during the initiation of GPP therapy. (See  <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">"Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Precipitating factors'</a>.)</p><p></p><p class="bulletIndent1">Patients in whom GPP was precipitated by an antipsoriatic drug may be best managed with an agent with a different mechanism of action. For example, the tumor necrosis factor (TNF)-alpha inhibitor <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> would be a less favorable choice for a patient with adalimumab-induced GPP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initiate treatment to control skin disease </strong>– Medical treatment options for GPP consist of systemic therapies, topical therapies, and phototherapy. We typically use systemic treatment for the initial management of adults because phototherapy tends to have a delayed onset of action and topical therapies are impractical for widespread disease. In addition to limiting factors, such as drug availability and patient-specific contraindications, the selection of an initial systemic therapy is based upon the acuity and severity of disease. Topical therapies primarily serve as adjuncts to systemic therapy in adults with GPP. (See <a class="local">'First-line pharmacologic therapy for adults'</a> below and <a class="local">'Adjunctive topical therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Manage extracutaneous complications </strong>– Extracutaneous complications, such as sepsis or internal organ dysfunction, should be managed appropriately. (See  <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">"Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Clinical course'</a>.)</p><p></p><p class="headingAnchor" id="H167785531"><span class="h2">First-line pharmacologic therapy for adults</span><span class="headingEndMark"> — </span>Our preferred first-line treatments for nonpregnant adults include <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, and various biologic therapies [<a href="#rid8">8-11</a>]. The approach to treatment selection differs for patients with tolerable, nondisabling disease and patients with severe, acute disease. (See <a class="local">'Tolerable, nondisabling disease'</a> below and <a class="local">'Severe, acute disease'</a> below.)</p><p class="headingAnchor" id="H86907155"><span class="h3">Tolerable, nondisabling disease</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">Acitretin</a> and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> are the preferred initial treatments for adults with relatively stable GPP. Advantages of these drugs include that they are relatively well tolerated, available in oral form, and can be used for long-term maintenance treatment. A disadvantage is their relatively slow onset of action; thus, an alternative approach is indicated for patients with more severe disease. (See <a class="local">'Severe, acute disease'</a> below.)</p><p>Data are insufficient to compare the efficacy of <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>. Selection between these drugs is based upon patient-specific factors, such as ability to tolerate side effects and contraindications. As an example, the requirement that women abstain from pregnancy for three years after acitretin treatment gives acitretin a relative contraindication for use in women of childbearing age.</p><p class="headingAnchor" id="H86907161"><span class="h4">Oral retinoids</span><span class="headingEndMark"> — </span>Oral retinoids that have been used for GPP include etretinate, <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> (a metabolite of etretinate), and <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>. Acitretin is our preferred oral retinoid because clinical experience with isotretinoin for this indication is more limited, and etretinate was withdrawn from United States market in 1998:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and precautions </strong>–<strong> </strong>Our usual starting dose for <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> is 0.75 to 1 mg/kg per day. Japanese guidelines have suggested an initial dose of etretinate of 0.5 to 1 mg/kg per day [<a href="#rid12">12</a>]. Improvement (ie, cessation of new pustule formation and initial improvement in other clinical signs) is usually noted within 7 to 10 days of oral retinoid therapy, and a complete response often requires two to three months of treatment. After disease control is achieved, the dose of acitretin can be tapered slowly to the lowest dose necessary to maintain improvement.</p><p></p><p class="bulletIndent1">Examples of adverse effects of oral retinoids include xerosis, cheilitis, dry mucous membranes, hypertriglyceridemia, hair loss, liver function test abnormalities, bone changes, and visual changes. Oral retinoids are teratogenic and pregnancy should be avoided for three years following <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> therapy. Therefore, the drug has a relative contraindication for women of childbearing age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– Evidence to support retinoid use is limited. Some support comes from a Japanese study that analyzed treatment data from 385 patients with acute GPP obtained through questionnaire responses from multiple community center hospitals [<a href="#rid13">13</a>]. The study found that among 188 patients treated with retinoids, treatment was reported as effective in 84 percent. Retinoid treatment regimens were not standardized; typically, treatment was with etretinate (1 mg/kg per day and tapered as tolerated). Many patients received retinoids in combination with other therapies. Data from a retrospective study also suggests benefit of etretinate [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1">In a series of 11 adults with GPP, <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> therapy seemed beneficial for improving pustule formation in 10 patients, although monotherapy with the drug did not seem to be effective for clearing all lesions [<a href="#rid15">15</a>]. Isotretinoin also appeared useful in an adolescent female who failed to respond adequately to topical corticosteroids and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid16">16</a>] and in two patients who did not tolerate <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> [<a href="#rid17">17</a>].</p><p></p><p class="headingAnchor" id="H86907167"><span class="h4">Methotrexate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> may be given subcutaneously or orally and appears to be effective for GPP:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and precautions </strong>–<strong> </strong>A typical dose of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> for adults with GPP is 15 mg per week, with a maximum dose of 25 mg per week. Methotrexate is <strong>not</strong> given daily. We often use subcutaneous, rather than oral, methotrexate given that absorption of oral methotrexate may be reduced at higher doses and bioavailability may be superior with subcutaneous dosing [<a href="#rid18">18-20</a>]. Significant clinical improvement is expected within 8 to 12 weeks.</p><p></p><p class="bulletIndent1">Myelosuppression is a potential serious adverse effect of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> that warrants careful administration of treatment and laboratory follow-up. The amount of methotrexate used for the initial dose varies among experts, with some experts initiating with a small test dose (eg, 5 mg per week) followed by upward titration of the dose and others initiating at higher doses (eg, 15 mg per week) [<a href="#rid21">21</a>]. When treating older adult patients or patients with renal insufficiency, the initial dose should not exceed 10 mg per week.</p><p></p><p class="bulletIndent1">Additional adverse effects of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> include gastrointestinal distress, hepatotoxicity, pulmonary toxicity, and teratogenicity. Methotrexate should be combined with <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> supplementation (eg, 1 mg of folic acid per day) to decrease hematologic and gastrointestinal toxicity [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a>.)</p><p></p><p class="bulletIndent1">Monitoring protocols for <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> treatment vary; in general, a complete blood count with differential and platelets should be performed at baseline and soon after the initiation of methotrexate and following dose increases. While some clinicians perform hematologic testing approximately one week after dose initiation or changes, others (including the author) perform tests after two to four weeks provided the patient is not an older adult individual and does not have renal insufficiency. Hematologic testing is repeated every two to four weeks during the first few months of treatment and is subsequently tapered to every one to three months. Periodic laboratory monitoring of kidney and liver function is also indicated during methotrexate therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>–<strong> </strong>Data on the efficacy of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> are limited. In a multicenter study in Japan in which community hospitals were sent questionnaires about patients with GPP, efficacy of methotrexate was documented for 76 percent of 41 patients given this therapy alone or in conjunction with other therapies [<a href="#rid13">13</a>]. In addition, in a retrospective study of 63 patients hospitalized for GPP at Mayo Clinic affiliated-hospitals between 1961 and 1989, good responses to methotrexate were reported for three of eight patients with acute GPP and both of two patients with annular pustular psoriasis [<a href="#rid14">14</a>]. </p><p></p><p class="headingAnchor" id="H90812547"><span class="h3">Severe, acute disease</span><span class="headingEndMark"> — </span>For patients with severe, acute disease that warrants rapid stabilization and improvement, we select faster-acting drugs, such as <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, and anti-interleukin (IL) 17 or anti-IL-23 biologic agents.</p><p class="headingAnchor" id="H256650271"><span class="h4">Treatment selection</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> and <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> have a longer history of use for GPP compared with anti-IL-17 and anti-IL-23 biologic agents and, historically, were considered the treatments of choice for severe, acute GPP. The emergence of reports suggesting benefit of anti-IL-17 and anti-IL-23 biologic agents has led to the inclusion of these drugs as first-line therapies for GPP [<a href="#rid8">8,23</a>].</p><p>Data comparing therapies for GPP are limited and insufficient for determining relative efficacy. Practical advantages of biologic IL-17 and IL-23 inhibitors include a more favorable side effect profile than <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and subcutaneous route of administration (in contrast to the intravenous administration of <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>).</p><p>Because rapid initiation of therapy is necessary for patients with severe, acute GPP, treatment availability often influences the selection of an initial treatment. Although we generally prefer to use a biologic anti-IL-17 or anti-IL-23 drug for initial therapy, we often find it necessary to use <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> for hospitalized patients because of greater availability of these drugs in the inpatient setting.</p><p>Once control of acute disease is achieved, patients may be maintained on fast-acting therapies or transitioned to <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> for long-term treatment. <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> is the exception; risk for serious side effects with prolonged cyclosporine therapy supports transitioning to other treatments.</p><p class="headingAnchor" id="H90812553"><span class="h4">Cyclosporine</span><span class="headingEndMark"> — </span>Oral <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> has a long history of use for psoriasis and can induce rapid improvement of GPP:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and precautions </strong>–<strong> </strong>Effective doses of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> for adults with GPP have ranged from 2.5 to 5 mg/kg per day [<a href="#rid24">24</a>]. We typically treat severe, acute GPP with 4 to 5 mg/kg (ideal body weight) per day. Marked improvement often occurs within the first few days of treatment [<a href="#rid1">1,25-27</a>]. Because side effects of cyclosporine are a concern, once disease control is achieved, we attempt to taper the dose over the course of two to three months and transition to other treatments.</p><p></p><p class="bulletIndent1">Potential adverse effects of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> include hypertension, renal toxicity, and increased risk for infections and malignancy. Laboratory tests as well as blood pressure should be monitored closely during therapy. Adverse effects of cyclosporine are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Side effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>–<strong> </strong>Despite the common use of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> for severe, acute GPP, data on the efficacy of the drug are limited. A beneficial effect of cyclosporine is supported by retrospective data obtained from hospitals in Japan that suggested treatment efficacy in 60 to 70 percent of patients treated with cyclosporine alone or in conjunction with other therapies [<a href="#rid13">13,28</a>].</p><p></p><p class="headingAnchor" id="H90812559"><span class="h4">Infliximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">Infliximab</a> is a TNF-alpha inhibitor given through intravenous infusion that may lead to rapid improvement in GPP:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and precautions </strong>–<strong> </strong>Standard dosing of <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> for psoriasis in adults is intravenous infusion of 5 mg/kg at weeks 0, 2, and 6, and every six to eight weeks thereafter. Marked improvement is usually evident within several days.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">Infliximab</a> may be continued for long-term management of GPP after control of acute disease is achieved. Alternatively, patients can be transitioned to other therapies.</p><p></p><p class="bulletIndent1">Potential adverse effects of <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> include infusion reactions and increased risk for infection (including herpes zoster), malignancy, heart failure, and demyelinating disease [<a href="#rid29">29,30</a>]. Patients should be evaluated for latent tuberculosis and hepatitis B prior to initiating therapy.</p><p></p><p class="bulletIndent1">There are also reports of <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> inducing psoriatic eruptions, including GPP [<a href="#rid7">7,31,32</a>]. The adverse effects of infliximab are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>–<strong> </strong>The use of <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> for GPP is based upon case reports and observational studies that suggest efficacy of this treatment [<a href="#rid8">8,30,33-43</a>].</p><p></p><p class="bulletIndent1">Among 10 patients in whom flares of acute GPP were treated with <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> in a French multicenter retrospective study, clinical remission was achieved by 8 patients (80 percent). The fast onset of infliximab was evident in the time required to achieve clearance of pustules; pustules cleared in a median of two days (range, one to eight days) [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1">A postmarketing surveillance study assessed the efficacy and safety of <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> over six months. Among 56 patients with pustular psoriasis disease severity assessments, the proportion with moderate or severe pustular psoriasis fell from 25 and 7 percent, respectively, at baseline to 2 and 4 percent, respectively, at the final assessment, suggesting benefit [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1">The possibility that a single dose of <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> may be sufficient is suggested by a case report documenting dramatic improvement in acute GPP within 24 hours following a single dose of infliximab followed by the initiation of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid34">34</a>]. Infliximab has also been successfully used in combination with <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> for the induction of rapid improvement while awaiting the onset of action of acitretin [<a href="#rid44">44</a>].</p><p></p><p class="headingAnchor" id="H4092634426"><span class="h4">IL-17 inhibitors</span><span class="headingEndMark"> — </span>IL-17 inhibitors used for GPP include <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> (an IL-17A inhibitor), <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a> (an IL-17A inhibitor), and <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">brodalumab</a> (an IL-17 receptor A inhibitor). Dosing generally reflects the recommended doses for plaque psoriasis. Optimal treatment regimens for GPP are unknown.</p><p>Examples of potential adverse effects of IL-17 inhibitors include injection site reactions and increased risk for upper respiratory tract infection, oral candidiasis, conjunctivitis, tinea infection, and inflammatory bowel disease. Although there has been concern for an increased risk for suicidal ideation and behavior in association with <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">brodalumab</a> therapy, a causative relationship has not been confirmed (see  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Brodalumab'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secukinumab</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Administration </strong>– Typical dosing for adults is 300 mg given subcutaneously once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every four weeks. Doses of 150 mg may be sufficient for some patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Efficacy </strong>–<strong> </strong>Benefit of <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> (an anti-IL-17A monoclonal antibody) for GPP is suggested in a 52-week, open-label study in which 12 adults with GPP received secukinumab (150 mg once weekly at baseline; weeks 1, 2, 3, and 4; and then every four weeks, with the option to increase the dose to 300 mg in patients who showed minimal or no improvement) [<a href="#rid45">45</a>]. Eight patients also received nonbiologic systemic therapies for psoriasis, but doses of these agents could not be increased. At week 16 (the primary endpoint), 10 patients (83 percent) received clinical global impression ratings of "very much improved" or "much improved." One patient showed no improvement, and a second patient discontinued treatment prior to 16 weeks due to a protocol deviation. Improvement was rapid, with maximum improvement achieved within three weeks. Response rates remained high at 52 weeks.</p><p></p><p class="bulletIndent2">Responses to <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> are also documented in case reports, including a patient with acute GPP who experienced complete resolution of pustulation within one week during treatment with secukinumab (300 mg given once weekly for three weeks) [<a href="#rid46">46-52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ixekizumab</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Administration</strong> – Typical dosing for adults is 160 mg given subcutaneously at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12. Subsequently, 80 mg are given every four weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Efficacy </strong>– <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">Ixekizumab</a> (an anti-IL-17A monoclonal antibody) may be beneficial based upon a 52-week, open-label study in which 78 patients with plaque psoriasis, erythrodermic psoriasis, or GPP received ixekizumab (160 mg at week 0, then 80 mg every two weeks until week 12, then 80 mg every four weeks). At week 12, four of the five patients with GPP achieved 75 percent improvement in the Psoriasis Area and Severity Index score (PASI 75), and three patients achieved 90 percent improvement (PASI 90) [<a href="#rid53">53</a>]. This level of response was sustained with continued treatment over three years [<a href="#rid54">54-56</a>]. Concomitant systemic glucocorticoid therapy equivalent to less than or equal to 10 mg per day of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> was permitted.</p><p></p><p class="bulletIndent2">Improvement in GPP with <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a> is also described in a case report and case series [<a href="#rid57">57,58</a>]. In a case series of 10 patients with refractory GPP treated with ixekizumab, all nine patients available for evaluation at week 12 achieved PASI 75 [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Brodalumab</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Administration</strong> – Typical dosing for adults is 210 mg given subcutaneously at weeks 0, 1, and 2 and then every two weeks. In the United States, <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">brodalumab</a> must be prescribed through a Risk Evaluation and Mitigation Strategy program due to concerns regarding risk for suicidal ideation and completed suicides in treated patients. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Brodalumab'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Efficacy </strong>– A 52-week, open-label study evaluating the efficacy of the anti-IL-17 receptor A monoclonal antibody <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">brodalumab</a> (140 mg at day 1, weeks 1 and 2, then every two weeks, with the option to increase the dose to 210 mg) for GPP and erythrodermic psoriasis found that 11 of 12 patients with GPP achieved a clinical global impression of "improved" or "remission" by week 52 [<a href="#rid59">59</a>]. Improvement was rapid, with 9 of 12 patients achieving this status at week 2. Concomitant treatment with stable or decreasing doses of systemic <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10047" href="/z/d/drug information/10047.html" rel="external">vitamin A</a> preparations, or glucocorticoids was permitted.</p><p></p><p class="headingAnchor" id="H439728733"><span class="h4">IL-23 inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">Ustekinumab</a> (an inhibitor of IL-12 and IL-23) and <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a> (and inhibitor of IL-23) have been used for GPP. Dosing generally reflects the recommended doses for plaque psoriasis. Optimal treatment regimens for GPP are unknown:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ustekinumab</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Administration </strong>– Dosing of <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a> is weight based. Typical dosing for adults ≤100 kg is 45 mg given subcutaneously at weeks 0, 4, and every 12 weeks thereafter. A 90 mg dose given in the same regimen is recommended for adults who weigh more than 100 kg.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Efficacy </strong>– Case reports and case series have documented efficacy of <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a> in acute pustular psoriasis [<a href="#rid60">60-63</a>]. In one report, all four patients responded well to therapy, including one who harbored an <em>IL36RN</em> mutation. Three of the four patients also received low-dose <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> [<a href="#rid61">61</a>]. The onset or worsening of pustular psoriasis following ustekinumab treatment has also been reported [<a href="#rid64">64-67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Guselkumab</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Administration </strong>– Typical dosing for adults is 100 mg given subcutaneously at weeks 0, 4, and then every 8 weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Efficacy </strong>– <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">Guselkumab</a> (a monoclonal antibody directed against the p19 subunit of IL-23) appeared beneficial in GPP and erythrodermic psoriasis in a 52-week, open-label study [<a href="#rid68">68</a>]. Ten patients with GPP were treated with 50 mg at weeks 0, 4, and every 8 weeks thereafter. The dose could be escalated to 100 mg at week 20 based on prespecified criteria, and patients were allowed to continue topical therapies and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>. Seven of the patients with GPP achieved the primary study endpoint of treatment success (at least minimal improvement based upon a Clinical Global Impression rating at week 16), including four who achieved greater than minimal improvement. Two patients discontinued the study due to lack of response and a diagnosis of cutaneous squamous cell carcinoma. All eight patients who completed the study had treatment success at 52 weeks.</p><p></p><p class="headingAnchor" id="H2043172868"><span class="h2">Adjunctive topical therapy</span><span class="headingEndMark"> — </span>Because of the widespread nature of GPP, topical medications are primarily reserved for adjunctive therapy.</p><p>Topical therapies that have seemed useful for adjunctive therapy in case reports are similar to those used in chronic plaque psoriasis and include topical corticosteroids [<a href="#rid69">69</a>], combination therapy with a topical corticosteroid and topical vitamin D analog [<a href="#rid70">70</a>], and topical <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> [<a href="#rid71">71</a>]. Topical corticosteroids are the topical agents we use most frequently.</p><p>The development of GPP in association with use of topical corticosteroids [<a href="#rid72">72-74</a>] and topical vitamin D analogs [<a href="#rid72">72,75,76</a>] has been reported. We aim to minimize this risk through focusing topical therapy on small areas of persistent or recalcitrant skin involvement [<a href="#rid24">24,77</a>].</p><p>A response of GPP to total body application of topical <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> has been reported [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H2751911018"><span class="h2">Second-line therapy for adults</span><span class="headingEndMark"> — </span>When patients do not respond to or cannot tolerate a first-line therapy, we typically select one of the other acceptable first-line therapies. (See <a class="local">'First-line pharmacologic therapy for adults'</a> above.)</p><p>Patients for whom this is not an option may benefit from other approaches to therapy, such as psoralen plus ultraviolet A (PUVA) photochemotherapy or additional biologic therapies.</p><p>PUVA photochemotherapy generally is not used as a first-line therapy because of a delayed onset of action and the frequent clinic visits (eg, often three times per week) necessary for treatment. Limited evidence for efficacy contributes to the status of some antipsoriatic biologic agents as second-line, rather than first-line, therapies:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psoralen plus ultraviolet A (PUVA) photochemotherapy </strong>–<strong> </strong>PUVA photochemotherapy involves the administration of photosensitizing psoralen orally or topically prior to exposure to an ultraviolet A (UVA) light source. Because of a relatively slow onset of action, PUVA photochemotherapy is typically reserved for patients who have already achieved control of acute disease.</p><p></p><p class="bulletIndent1">In an uncontrolled prospective study of eight patients with acute GPP, oral PUVA photochemotherapy (four times weekly) was associated with complete clearing of GPP in all patients within a mean of 13.5±10 treatment sessions [<a href="#rid79">79</a>]. Maintenance therapy (twice weekly PUVA treatments tapered to discontinuation if tolerated) was given upon complete remission, and seven patients remained in complete remission during follow-up periods of up to 1.5 years. The frequent clinic visits required for PUVA photochemotherapy make this a less favorable treatment option for some patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other biologic agents </strong>– Successful control of GPP during treatment with anti-TNF biologic agents other than <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> (eg, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, certolizumab, <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>) has been reported in small numbers of patients [<a href="#rid33">33,80-86</a>]. A phase 3 trial is evaluating efficacy of <a class="drug drug_general" data-topicid="121112" href="/z/d/drug information/121112.html" rel="external">risankizumab</a>, an IL-23 inhibitor.</p><p></p><p class="bulletIndent1">In an open-label study in which 10 patients with GPP received <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> (40 or 80 mg every other week after an 80 mg initial dose), 7 patients achieved partial or complete improvement by week 16 [<a href="#rid31">31</a>]. In a retrospective study, two of three GPP flares treated with adalimumab progressed to clinical remissions, and clearance of pustules occurred within 7 and 28 days [<a href="#rid33">33</a>]. Of note, there are reports of TNF-alpha inhibitors inducing pustular psoriasis, including GPP [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination therapy </strong>– Several case reports demonstrate efficacy in recalcitrant GPP when two or more classes of therapeutic agents are used in combination. Examples include <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid26">26</a>], <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid41">41,87</a>], <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> and <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> [<a href="#rid88">88</a>], adalimumab and methotrexate [<a href="#rid89">89</a>], infliximab and acitretin [<a href="#rid44">44</a>], <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> and <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a> [<a href="#rid90">90</a>], <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a> and colchicine [<a href="#rid90">90</a>], acitretin and glycyrrhizin (a hepatoprotective constituent of Chinese herbal medicine) [<a href="#rid91">91</a>], and cyclosporine and PUVA photochemotherapy [<a href="#rid25">25</a>]. In addition, children have responded to combination therapy with narrowband ultraviolet B (UVB) and systemic therapies [<a href="#rid92">92,93</a>] as well as infliximab combined with methotrexate [<a href="#rid87">87</a>].</p><p></p><p class="headingAnchor" id="H167785567"><span class="h2">Other therapies</span><span class="headingEndMark"> — </span>A variety of other therapies have been used for GPP, although concern for side effects or limited experience precludes a recommendation for the routine use of these therapies:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic glucocorticoids </strong>– Although systemic glucocorticoid therapy can lead to rapid improvement in GPP [<a href="#rid28">28</a>], the treatment must be used with caution because systemic glucocorticoids are implicated as potential inciting factors for GPP [<a href="#rid24">24</a>]. In addition, there is concern for the serious side effects from long-term glucocorticoid therapy. Thus, we do not typically use systemic glucocorticoids. In the event that systemic glucocorticoid treatment is given to obtain initial control of GPP, we suggest also initiating a second therapy in an attempt to reduce the likelihood of a disease flare during tapering and discontinuation of the systemic glucocorticoid. However, evidence to support this approach is lacking. The adverse effects of systemic glucocorticoids are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spesolimab</strong><strong> </strong>– A 12-week, phase 2 trial suggests benefit of <a class="drug drug_general" data-topicid="139549" href="/z/d/drug information/139549.html" rel="external">spesolimab</a>, a monoclonal antibody that targets the IL-36 receptor [<a href="#rid94">94</a>]. In the trial, 53 adults with a moderate to severe GPP flare were randomly assigned in a 2:1 ratio to receive a single 900 mg subcutaneous dose of spesolimab or placebo on day 1, with options for open-label spesolimab on day 8 based upon response and subsequent open-label spesolimab as a rescue treatment. At day 8, 18 of 35 patients (54 percent) in the spesolimab group achieved a GPP Physician Global Assessment score of 0 (no visible pustules) compared with only 1 of 18 (6 percent) in the placebo group (difference 32 percentage points, 95% CI 2-53). Infections occurred in 17 percent of patients in the spesolimab group and 6 percent in the placebo group in week 1. Over 12 weeks, serious adverse events occurred in 6 of 51 patients (12 percent) who received at least one dose of spesolimab, including two patients with drug reaction with eosinophilia and systemic symptoms (DRESS). (See  <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other </strong>– Several case reports document the successful use of granulocyte and monocyte apheresis for the treatment of refractory GPP, including a report of use in a patient harboring the <em>IL36RN</em> mutation [<a href="#rid95">95-102</a>]. Other treatments that have been reported to be effective for GPP in case reports include <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a> [<a href="#rid98">98,103,104</a>], <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">canakinumab</a> [<a href="#rid105">105</a>], <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil [<a href="#rid106">106</a>], oral zinc [<a href="#rid107">107</a>], <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> [<a href="#rid108">108</a>], and <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a> [<a href="#rid109">109</a>]. It remains to be seen whether anakinra is primarily effective for GPP associated with deficiency of the interleukin-36-receptor antagonist (DITRA). (See <a class="local">'IL36RN mutations'</a> below.)</p><p></p><p class="bulletIndent1">The efficacy of other biologic agents for GPP is unclear. Clinical trials are underway for several therapies.</p><p></p><p class="headingAnchor" id="H167785573"><span class="h2">Special populations</span></p><p class="headingAnchor" id="H167785579"><span class="h3">Children</span><span class="headingEndMark"> — </span>Childhood GPP is rare, contributing to a paucity of data on the efficacy and safety of treatments for GPP in children. As in adults, oral retinoids, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, TNF-alpha inhibitors, <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>, and <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a> have been used for the treatment of children [<a href="#rid110">110</a>].</p><p class="headingAnchor" id="H637545470"><span class="h4">Acute generalized pustular psoriasis</span><span class="headingEndMark"> — </span>No randomized trials have evaluated the efficacy of treatments for acute GPP in children. Treatment selection is primarily based upon case reports or case series that suggest efficacy of these drugs in children with GPP and experience with these agents for other forms of psoriasis in children [<a href="#rid110">110</a>]. Benefit has been described for oral retinoids [<a href="#rid16">16,77,111-115</a>], <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid27">27,93,116-120</a>], <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid113">113,121,122</a>], <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> [<a href="#rid87">87,123-126</a>], <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> [<a href="#rid80">80,127,128</a>], <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid123">123,126,129</a>], and <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> [<a href="#rid130">130-132</a>]. We consider the following agents appropriate initial treatment choices for children with GPP: </p><p class="bulletIndent1"><span class="glyph">●</span>Tolerable, nondisabling disease:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">Acitretin</a> (less than 1 mg/kg per day) </p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> (0.2 to 0.4 mg/kg per <strong>week</strong>) </p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">Etanercept</a> (&lt;63 kg: 0.8 mg/kg once per week; ≥63 kg: 50 mg once per week)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe, acute disease:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> (1 to 3 mg/kg per day)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">Infliximab</a> (5 mg/kg at weeks 0, 2, and 6, then every six to eight weeks if continuation of therapy is needed)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">Secukinumab</a> (for children &lt;50 kg, 75 mg; for children ≥50 kg, 150 mg given at weeks 0, 1, 2, 3, and 4 and then every 4 weeks)</p><p></p><p>As in adults, children requiring <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> for severe disease may be transitioned to other therapies after achievement of control of disease [<a href="#rid133">133</a>]. Long-term treatment with cyclosporine is not recommended due to risk for serious side effects. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Side effects'</a>.)</p><p>In particular, randomized trials supporting the efficacy and safety of <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> for moderate to severe plaque psoriasis in children have contributed to use of etanercept as a first-line therapy in the pediatric population [<a href="#rid134">134-136</a>]. However, evidence for efficacy of etanercept in GPP is very limited, and etanercept is not typically used as a first-line therapy in adults.</p><p>Given the contraindication for pregnancy during <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> treatment and for three years after drug discontinuation, the use of acitretin in female children and adolescents must be considered carefully. Successful treatment with <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a> in place of acitretin has been reported in an adolescent female [<a href="#rid16">16</a>]. A slight risk for skeletal toxicity has been observed in children treated with high doses of oral retinoids for disorders of keratinization [<a href="#rid137">137</a>].</p><p>Additional therapies that may be useful in the treatment of pediatric acute GPP based upon case reports include narrowband UVB phototherapy in conjunction with systemic therapy [<a href="#rid92">92,93</a>], <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> [<a href="#rid80">80</a>], and the combination of <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid87">87</a>]. Also, an infant with GPP associated with DITRA has responded to <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a> [<a href="#rid138">138</a>], and an adolescent with DITRA achieved a rapid clinical response and sustained remission during treatment with <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H4041220466"><span class="h4">Generalized annular pustular psoriasis</span><span class="headingEndMark"> — </span>Topical corticosteroid therapy may be effective for the treatment of children with annular pustular psoriasis, which exhibits less severe manifestations than acute GPP [<a href="#rid5">5</a>]. In addition, topical compresses, wet wraps, or oatmeal baths may be helpful for soothing the skin lesions [<a href="#rid5">5,139</a>]. </p><p>Topical therapy for annular pustular psoriasis is less practical when a large proportion of the body surface is affected. Patients who cannot be managed only with topical therapy can be treated with systemic agents. Case reports suggest that oral retinoids, oral <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> can be effective for this variant [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H167785585"><span class="h3">Pregnant women</span><span class="headingEndMark"> — </span>The management of pustular psoriasis in pregnancy (impetigo herpetiformis) is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5564.html" rel="external">"Dermatoses of pregnancy", section on 'Pustular psoriasis of pregnancy'</a>.)</p><p class="headingAnchor" id="H54691300"><span class="h3">IL36RN mutations</span><span class="headingEndMark"> — </span>Growing understanding of the molecular basis of GPP associated with <em>IL36RN</em> mutations may aid in therapeutic decisions for patients with this type of GPP [<a href="#rid140">140</a>]. Evidence suggests that some cases of GPP (or acute generalized exanthematous pustulosis [AGEP]) may actually represent a new genetic autoinflammatory disease based on mutations in the <em>IL36RN</em> gene, which encodes the IL-36 receptor antagonist. This disease is known as DITRA. (See  <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">"Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p>Patients with <em>IL36RN</em> mutations upregulate IL-1 in response to IL-36 stimulation. Case reports documenting successful treatment of GPP in patients with <em>IL36RN</em> mutations with <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a>, an IL-1 receptor antagonist, support the importance of this pathway [<a href="#rid104">104,138</a>]. In addition, preliminary findings of clinical trials suggest that treatment with IL-1 antagonists can improve GPP  (<a class="graphic graphic_picture graphicRef95263" href="/z/d/graphic/95263.html" rel="external">picture 2</a>) [<a href="#rid105">105,141</a>]. As more data accumulate, IL-1 blockade may become the treatment of choice for patients who harbor the genetic mutation.</p><p>The beneficial effects of systemic therapy, such as <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, TNF-inhibiting drugs, and anti-IL-17/23 antibodies, for GPP appear independent of the presence of the <em>IL36RN</em> mutation [<a href="#rid42">42,61,125,142-144</a>]. Whether agents targeting the IL-36 pathway or IL-1 will be more effective and/or safer for patients with the mutation remains to be determined.</p><p class="headingAnchor" id="H167787006"><span class="h1">LOCALIZED PUSTULAR PSORIASIS</span><span class="headingEndMark"> — </span>The approach to the treatment of pustular psoriasis differs from generalized pustular psoriasis (GPP). Local treatment generally is used as first-line treatment, with systemic therapies reserved for patients who fail to respond well to local therapy.</p><p class="headingAnchor" id="H90813581"><span class="h2">Acrodermatitis continua of Hallopeau</span><span class="headingEndMark"> — </span>Acrodermatitis continua of Hallopeau (ACH) is a rare, chronic, localized form of pustular psoriasis that primarily involves one or more extremity digits  (<a class="graphic graphic_picture graphicRef94791" href="/z/d/graphic/94791.html" rel="external">picture 3</a>). ACH is often poorly responsive to therapy. (See  <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">"Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Acrodermatitis continua of Hallopeau'</a>.)</p><p>A variety of local and systemic therapies have been utilized for ACH with variable results. Data on the treatment of this rare disease are primarily limited to case reports and case series. Topical corticosteroids, topical <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, topical <a class="drug drug_general" data-topicid="9181" href="/z/d/drug information/9181.html" rel="external">calcipotriol</a> (alone or in combination with topical corticosteroids or topical tacrolimus), <a class="drug drug_general" data-topicid="91010" href="/z/d/drug information/91010.html" rel="external">topical mechlorethamine</a> hydrochloride, topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>, psoralens plus ultraviolet A (PUVA) photochemotherapy, narrowband ultraviolet B (UVB) phototherapy, ultraviolet A1 (UVA1) phototherapy, and brachytherapy are among the local treatments documented as effective in individual patients with ACH [<a href="#rid145">145-148</a>]. Systemic therapies have included oral retinoids, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, systemic glucocorticoids, methotrexate and <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">propylthiouracil</a>, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>, <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>, and <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a> [<a href="#rid145">145,149-155</a>]. The efficacies of these interventions have not been compared, and the best approach to treatment is unclear.</p><p>Our initial choice for treatment of ACH is typically a superpotent topical corticosteroid (eg, <a class="drug drug_general" data-topicid="8514" href="/z/d/drug information/8514.html" rel="external">halobetasol</a> or <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">clobetasol</a>), which we instruct the patient to apply to the affected areas once to twice daily for two to four weeks  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 1</a>). Preferably, the patient should apply the medication under an occlusive dressing at night, particularly during the first week of therapy. Plastic wrap is commonly used as an occlusive dressing. Alternatively, occlusion can be applied using damp cloth covered by dry cloth.</p><p>If a good response to treatment occurs, the frequency of application can be tapered as tolerated to a frequency as low as once or twice per week. Alternatively, we prescribe a topical vitamin D analog (eg, topical <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> or calcipotriene) in conjunction with the superpotent topical corticosteroid and instruct the patient to apply the topical corticosteroid followed immediately by the vitamin D analog once to twice daily for two to four weeks. Once sufficient improvement is achieved, we taper the topical corticosteroid as tolerated and continue treatment with the vitamin D analog. A commercial product containing both <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> dipropionate and calcipotriene is available.</p><p>When patients fail to respond adequately to topical therapy, we proceed to local phototherapy or systemic therapy, although we usually continue to use topical corticosteroids as adjunctive therapy. PUVA photochemotherapy, narrowband UVB, and UVA1 therapy have appeared effective for ACH [<a href="#rid145">145,147,148</a>]. We often use <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> (0.5 to 1 mg/kg per day) as our first-line systemic treatment, with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> as alternatives. For patients with severe disease and who are at risk for nail loss, we tend to prescribe biologic therapy.</p><p>If a patient fails to improve with traditional systemic therapies or presents with severe ACH, we often proceed to a biologic tumor necrosis factor (TNF)-alpha inhibitor, an anti-interleukin (IL) 12/23 therapy, or an anti-IL-17 therapy, such as <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>, <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a>, <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">brodalumab</a>, or <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a> [<a href="#rid156">156-162</a>]. The response to biologic therapy varies, and data are insufficient for conclusions on the most effective therapies [<a href="#rid163">163,164</a>].</p><p class="headingAnchor" id="H54690938"><span class="h2">Palmoplantar pustulosis</span><span class="headingEndMark"> — </span>Palmoplantar pustulosis is a chronic condition characterized by the development of yellow to brown pustules, scale, and patchy erythema on the palms or soles. It is controversial whether palmoplantar pustulosis is a localized variant of pustular psoriasis (palmoplantar pustular psoriasis) or a separate entity. The treatment of palmoplantar pustulosis is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/89272.html" rel="external">"Palmoplantar pustulosis: Epidemiology, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/93852.html" rel="external">"Palmoplantar pustulosis: Treatment"</a>.)</p><p class="headingAnchor" id="H3818047092"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112498.html" rel="external">"Society guideline links: Psoriasis"</a>.)</p><p class="headingAnchor" id="H633438"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease overview </strong>– Generalized pustular psoriasis (GPP) is an uncommon form of psoriasis characterized by the development of widespread pustules and erythematous plaques on the skin. The goals of treatment are to improve skin manifestations, alleviate systemic symptoms, and prevent serious or life-threatening complications of this disease. (See <a class="local">'Generalized pustular psoriasis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to therapy </strong>– Treatment options for adults with GPP include topical therapies, systemic therapies, and phototherapy. Most patients require systemic therapy. Topical therapies are primarily used as adjuncts to systemic therapy (see <a class="local">'Approach to therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Important interventions </strong>– As part of the initial management of patients with GPP, the need for hospitalization should be assessed. In addition, the patient's medical history should be reviewed for drugs that may contribute to the development of GPP. (See <a class="local">'Approach to therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial treatment for adults </strong>– The approach to the treatment of GPP is influenced by the acuity and severity of symptoms. For adult patients with relatively stable disease, we suggest <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> as initial therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For adult patients with severe, acute GPP, we suggest initial therapy with fast-acting therapies, such as <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, or select anti-interleukin (IL) 17/23 therapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'First-line pharmacologic therapy for adults'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial treatment for children </strong>– Data on the treatment of acute GPP in children are very limited. Options for first-line therapy include <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, and <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>. Some children with annular pustular psoriasis can be managed with topical treatment. (See <a class="local">'Children'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other therapies </strong>– Other therapeutic agents that may be effective in adults with GPP include psoralen plus ultraviolet A (PUVA) photochemotherapy, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, and <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>. Combination therapy with more than one treatment can also be attempted. (See <a class="local">'Second-line therapy for adults'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of systemic glucocorticoids </strong>– Systemic glucocorticoids can induce rapid improvement in GPP but have been identified as potential inciting factors for this disease. We do not usually use systemic glucocorticoids for the treatment of GPP. (See <a class="local">'Other therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of </strong><strong><em>IL36RN</em></strong><strong> mutations </strong>– Increasing knowledge about the pathogenesis of GPP associated with <em>IL36RN</em> mutations may lead to new therapeutic options for this form of GPP. (See <a class="local">'IL36RN mutations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acrodermatitis continua of Hallopeau </strong>– Acrodermatitis continua of Hallopeau (ACH) is a rare form of localized pustular psoriasis that primarily affects the extremity digits and is often refractory to treatment. Data on treatments for ACH are limited to case reports. We suggest a superpotent topical corticosteroid as initial treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Acrodermatitis continua of Hallopeau'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Varman KM, Namias N, Schulman CI, Pizano LR. Acute generalized pustular psoriasis, von Zumbusch type, treated in the burn unit. A review of clinical features and new therapeutics. Burns 2014; 40:e35.</a></li><li><a class="nounderline abstract_t">Allez M, Roux ME, Bertheau P, et al. Recurrent cholestatic jaundice associated with generalized pustular psoriasis: evidence for a neutrophilic cholangitis. J Hepatol 2000; 33:160.</a></li><li><a class="nounderline abstract_t">Li SP, Tang WY, Lam WY, Wong SN. Renal failure and cholestatic jaundice as unusual complications of childhood pustular psoriasis. Br J Dermatol 2000; 143:1292.</a></li><li><a class="nounderline abstract_t">Choon SE, Lai NM, Mohammad NA, et al. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2014; 53:676.</a></li><li><a class="nounderline abstract_t">Liao PB, Rubinson R, Howard R, et al. Annular pustular psoriasis--most common form of pustular psoriasis in children: report of three cases and review of the literature. Pediatr Dermatol 2002; 19:19.</a></li><li><a class="nounderline abstract_t">Takeichi T, Akiyama M. Generalized Pustular Psoriasis: Clinical Management and Update on Autoinflammatory Aspects. Am J Clin Dermatol 2020; 21:227.</a></li><li><a class="nounderline abstract_t">Zheng J, Gao Y, Ding Y. Successful management of infliximab-induced generalized pustular psoriasis without therapy discontinuation in a patient with psoriatic arthritis. Dermatol Ther 2019; 32:e13132.</a></li><li><a class="nounderline abstract_t">Falto-Aizpurua LA, Martin-Garcia RF, Carrasquillo OY, et al. Biological therapy for pustular psoriasis: a systematic review. Int J Dermatol 2020; 59:284.</a></li><li><a class="nounderline abstract_t">Wang WM, Jin HZ. Biologics in the treatment of pustular psoriasis. Expert Opin Drug Saf 2020; 19:969.</a></li><li><a class="nounderline abstract_t">Kearns DG, Chat VS, Zang PD, et al. Review of treatments for generalized pustular psoriasis. J Dermatolog Treat 2021; 32:492.</a></li><li><a class="nounderline abstract_t">Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol 2019; 15:907.</a></li><li><a class="nounderline abstract_t">Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP. J Dermatol 2018; 45:1235.</a></li><li><a class="nounderline abstract_t">Ozawa A, Ohkido M, Haruki Y, et al. Treatments of generalized pustular psoriasis: a multicenter study in Japan. J Dermatol 1999; 26:141.</a></li><li><a class="nounderline abstract_t">Zelickson BD, Muller SA. Generalized pustular psoriasis. A review of 63 cases. Arch Dermatol 1991; 127:1339.</a></li><li><a class="nounderline abstract_t">Moy RL, Kingston TP, Lowe NJ. Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis. Arch Dermatol 1985; 121:1297.</a></li><li><a class="nounderline abstract_t">Al-Shobaili H, Al-Khenaizan S. Childhood generalized pustular psoriasis: successful treatment with isotretinoin. Pediatr Dermatol 2007; 24:563.</a></li><li><a class="nounderline abstract_t">Wilken R, Sharma A, Patel F, Maverakis E. Successful treatment of palmoplantar pustulosis with isotretinoin. Dermatol Online J 2015; 21.</a></li><li><a class="nounderline abstract_t">Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004; 31:645.</a></li><li><a class="nounderline abstract_t">Cipriani P, Ruscitti P, Carubbi F, et al. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms. Clin Ther 2014; 36:427.</a></li><li><a class="nounderline abstract_t">Vena GA, Cassano N, Iannone F. Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis. Ther Clin Risk Manag 2018; 14:105.</a></li><li><a class="nounderline abstract_t">Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60:824.</a></li><li><a class="nounderline abstract_t">Al-Dabagh A, Davis SA, Kinney MA, et al. The effect of folate supplementation on methotrexate efficacy and toxicity in psoriasis patients and folic acid use by dermatologists in the USA. Am J Clin Dermatol 2013; 14:155.</a></li><li><a class="nounderline abstract_t">Miyachi H, Konishi T, Kumazawa R, et al. Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in Japan. J Am Acad Dermatol 2022; 86:1266.</a></li><li><a class="nounderline abstract_t">Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2012; 67:279.</a></li><li><a class="nounderline abstract_t">Hunt MJ, Lee SH, Salisbury EL, et al. Generalized pustular psoriasis responsive to PUVA and oral cyclosporin therapy. Australas J Dermatol 1997; 38:199.</a></li><li><a class="nounderline abstract_t">Vine K, Votava HJ, Smith BL. Generalized pustular psoriasis of Zambusch: case report of successful disease control with cyclosporine and etanercept. Cutis 2012; 90:132.</a></li><li><a class="nounderline abstract_t">Takahashi M, Takeuchi M, Matsunaga K. Infant with generalized pustular psoriasis who responded to cyclosporin A therapy. J Dermatol 2015; 42:911.</a></li><li><a class="nounderline abstract_t">Umezawa Y, Ozawa A, Kawasima T, et al. Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Res 2003; 295 Suppl 1:S43.</a></li><li><a class="nounderline abstract_t">Chen W, Peng C, Ding Y, et al. Development of herpes zoster during infliximab treatment for pediatric generalized pustular psoriasis: A case report. Dermatol Ther 2019; 32:e12838.</a></li><li><a class="nounderline abstract_t">Torii H, Terui T, Matsukawa M, et al. Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: Results from the prospective post-marketing surveillance. J Dermatol 2016; 43:767.</a></li><li><a class="nounderline abstract_t">Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol 2012; 67:e179.</a></li><li><a class="nounderline abstract_t">Almutairi D, Sheasgreen C, Weizman A, Alavi A. Generalized Pustular Psoriasis Induced by Infliximab in a Patient With Inflammatory Bowel Disease. J Cutan Med Surg 2018; 22:507.</a></li><li><a class="nounderline abstract_t">Viguier M, Aubin F, Delaporte E, et al. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis. Arch Dermatol 2012; 148:1423.</a></li><li><a class="nounderline abstract_t">Smith N, Harms KL, Hines AC, et al. Acute treatment of generalized pustular psoriasis of von Zumbusch with single-dose infliximab. J Am Acad Dermatol 2013; 68:e187.</a></li><li><a class="nounderline abstract_t">Vieira Serrão V, Martins A, Lopes MJ. Infliximab in recalcitrant generalized pustular arthropatic psoriasis. Eur J Dermatol 2008; 18:71.</a></li><li><a class="nounderline abstract_t">Lewis TG, Tuchinda C, Lim HW, Wong HK. Life-threatening pustular and erythrodermic psoriasis responding to infliximab. J Drugs Dermatol 2006; 5:546.</a></li><li><a class="nounderline abstract_t">Trent JT, Kerdel FA. Successful treatment of Von Zumbusch pustular psoriasis with infliximab. J Cutan Med Surg 2004; 8:224.</a></li><li><a class="nounderline abstract_t">Yawalkar N, Hunger RE. Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and adalimumab. Dermatology 2009; 218:79.</a></li><li><a class="nounderline abstract_t">Benoit S, Toksoy A, Bröcker EB, et al. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol 2004; 150:1009.</a></li><li><a class="nounderline abstract_t">Schmick K, Grabbe J. Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab). Br J Dermatol 2004; 150:367.</a></li><li><a class="nounderline abstract_t">Barland C, Kerdel FA. Addition of low-dose methotrexate to infliximab in the treatment of a patient with severe, recalcitrant pustular psoriasis. Arch Dermatol 2003; 139:949.</a></li><li><a class="nounderline abstract_t">Sugiura K, Endo K, Akasaka T, Akiyama M. Successful treatment with infliximab of sibling cases with generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist. J Eur Acad Dermatol Venereol 2015; 29:2054.</a></li><li><a class="nounderline abstract_t">Kim HS, You HS, Cho HH, et al. Two cases of generalized pustular psoriasis: successful treatment with infliximab. Ann Dermatol 2014; 26:787.</a></li><li><a class="nounderline abstract_t">Tang MM, Spanou Z, Tang H, et al. Rapid downregulation of innate immune cells, interleukin-12 and interleukin-23 in generalized pustular psoriasis with infliximab in combination with acitretin. Dermatology 2012; 225:338.</a></li><li><a class="nounderline abstract_t">Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol 2016; 43:1011.</a></li><li><a class="nounderline abstract_t">Böhner A, Roenneberg S, Eyerich K, et al. Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab. JAMA Dermatol 2016; 152:482.</a></li><li><a class="nounderline abstract_t">Polesie S, Lidholm AG. Secukinumab in the Treatment of Generalized Pustular Psoriasis: A Case report. Acta Derm Venereol 2017; 97:124.</a></li><li><a class="nounderline abstract_t">Cordoro KM, Ucmak D, Hitraya-Low M, et al. Response to Interleukin (IL)-17 Inhibition in an Adolescent With Severe Manifestations of IL-36 Receptor Antagonist Deficiency (DITRA). JAMA Dermatol 2017; 153:106.</a></li><li><a class="nounderline abstract_t">Mugheddu C, Atzori L, Lappi A, et al. Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis. J Eur Acad Dermatol Venereol 2017; 31:e420.</a></li><li><a class="nounderline abstract_t">Yeung J, Valbuena V. Successful use of secukinumab in pustular psoriasis. JAAD Case Rep 2016; 2:470.</a></li><li><a class="nounderline abstract_t">Sun ZL, Liu ZL, Xu YY, et al. Successful treatment of generalized pustular psoriasis with secukinumab: a report of two cases. Chin Med J (Engl) 2020; 133:3015.</a></li><li><a class="nounderline abstract_t">Akaji K, Nakagawa Y, Kakuda K, et al. Generalized pustular psoriasis associated with systemic lupus erythematosus successfully treated with secukinumab. J Dermatol 2021; 48:e43.</a></li><li><a class="nounderline abstract_t">Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol 2015; 29:1148.</a></li><li><a class="nounderline abstract_t">Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol 2017; 44:355.</a></li><li><a class="nounderline abstract_t">Egawa G, Honda T, Kabashima K. Long-term efficacy of ixekizumab in erythrodermic and generalized pustular psoriasis patients. J Eur Acad Dermatol Venereol 2019; 33:259.</a></li><li><a class="nounderline abstract_t">Okubo Y, Mabuchi T, Iwatsuki K, et al. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J). J Eur Acad Dermatol Venereol 2019; 33:325.</a></li><li><a class="nounderline abstract_t">Nagata M, Kamata M, Fukaya S, et al. Real-world single-center experience with 10 cases of generalized pustular psoriasis successfully treated with ixekizumab. J Am Acad Dermatol 2020; 82:758.</a></li><li><a class="nounderline abstract_t">Dattola A, Manfreda V, Esposito M, et al. A case of generalized pustular psoriasis and arthritis treated with ixekizumab. J Dermatolog Treat 2020; 31:754.</a></li><li><a class="nounderline abstract_t">Yamasaki K, Nakagawa H, Kubo Y, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol 2017; 176:741.</a></li><li><a class="nounderline abstract_t">Daudén E, Santiago-et-Sánchez-Mateos D, Sotomayor-López E, García-Díez A. Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis. Br J Dermatol 2010; 163:1346.</a></li><li><a class="nounderline abstract_t">Arakawa A, Ruzicka T, Prinz JC. Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status. JAMA Dermatol 2016; 152:825.</a></li><li><a class="nounderline abstract_t">Schnabel V, Broekaert SMC, Schön MP, Mössner R. Clearance of annular pustular psoriasis with ustekinumab. Eur J Dermatol 2017; 27:296.</a></li><li><a class="nounderline abstract_t">Storan ER, O'Gorman SM, Markham T. Generalized pustular psoriasis treated with ustekinumab. Clin Exp Dermatol 2016; 41:689.</a></li><li><a class="nounderline abstract_t">Wenk KS, Claros JM, Ehrlich A. Flare of pustular psoriasis after initiating ustekinumab therapy. J Dermatolog Treat 2012; 23:212.</a></li><li><a class="nounderline abstract_t">Gregoriou S, Kazakos C, Christofidou E, et al. Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis. Eur J Dermatol 2011; 21:104.</a></li><li><a class="nounderline abstract_t">Benzaquen M, Flachaire B, Rouby F, et al. Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn's disease-associated spondyloarthropathy. Rheumatol Int 2018; 38:1297.</a></li><li><a class="nounderline abstract_t">Hay RA, Pan JY. Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to adalimumab therapy. Clin Exp Dermatol 2014; 39:751.</a></li><li><a class="nounderline abstract_t">Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol 2018; 45:529.</a></li><li><a class="nounderline abstract_t">Vun YY, Jones B, Al-Mudhaffer M, Egan C. Generalized pustular psoriasis of pregnancy treated with narrowband UVB and topical steroids. J Am Acad Dermatol 2006; 54:S28.</a></li><li><a class="nounderline abstract_t">Kim BS, Jang HS, Jwa SW, et al. Generalized pustular psoriasis and hepatic dysfunction associated with oral terbinafine therapy. J Korean Med Sci 2007; 22:167.</a></li><li><a class="nounderline abstract_t">Rodríguez García F, Fagundo González E, Cabrera-Paz R, et al. Generalized pustular psoriasis successfully treated with topical tacrolimus. Br J Dermatol 2005; 152:587.</a></li><li><a class="nounderline abstract_t">Tobin AM, Langan SM, Collins P, Kirby B. Generalized pustular psoriasis (von Zumbusch) following the use of calcipotriol and betamethasone dipropionate ointment: a report of two cases. Clin Exp Dermatol 2009; 34:629.</a></li><li><a class="nounderline abstract_t">Ricotti C, Kerdel FA. Subacute annular generalized pustular psoriasis treated with etanercept and cyclosporine combination. J Drugs Dermatol 2007; 6:738.</a></li><li><a class="nounderline abstract_t">Augey F, Dissard C, Normand I, Daumont M. Generalized pustular psoriasis (von Zumbusch) following iatrogenic hypocortisolism. Eur J Dermatol 2004; 14:415.</a></li><li><a class="nounderline abstract_t">Georgala S, Rigopoulos D, Aroni K, Stratigos JT. Generalized pustular psoriasis precipitated by topical calcipotriol cream. Int J Dermatol 1994; 33:515.</a></li><li><a class="nounderline abstract_t">Tamiya H, Fukai K, Moriwaki K, Ishii M. Generalized pustular psoriasis precipitated by topical calcipotriol ointment. Int J Dermatol 2005; 44:791.</a></li><li><a class="nounderline abstract_t">Umezawa Y, Mabuch T, Ozawa A. Generalized pustular psoriasis in a child: observation of long-term combination therapy with etretinate and calcipotriol for 16 years. Pediatr Dermatol 2012; 29:206.</a></li><li><a class="nounderline abstract_t">Nagao K, Ishiko A, Yokoyama T, et al. A case of generalized pustular psoriasis treated with topical tacrolimus. Arch Dermatol 2003; 139:1219.</a></li><li><a class="nounderline abstract_t">Hönigsmann H, Gschnait F, Konrad K, Wolff K. Photochemotherapy for pustular psoriasis (von Zumbusch). Br J Dermatol 1977; 97:119.</a></li><li><a class="nounderline abstract_t">Callen JP, Jackson JH. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent. J Dermatolog Treat 2005; 16:350.</a></li><li><a class="nounderline abstract_t">Zangrilli A, Papoutsaki M, Talamonti M, Chimenti S. Long-term efficacy of adalimumab in generalized pustular psoriasis. J Dermatolog Treat 2008; 19:185.</a></li><li><a class="nounderline abstract_t">Kimura U, Kinoshita A, Sekigawa I, et al. Successful treatment with adalimumab in a patient with psoriatic arthritis and generalized pustular psoriasis. J Dermatol 2012; 39:1071.</a></li><li><a class="nounderline abstract_t">Lo Schiavo A, Brancaccio G, Puca RV, Caccavale S. Etanercept in the treatment of generalized annular pustular psoriasis. Ann Dermatol 2012; 24:233.</a></li><li><a class="nounderline abstract_t">Esposito M, Mazzotta A, Casciello C, Chimenti S. Etanercept at different dosages in the treatment of generalized pustular psoriasis: a case series. Dermatology 2008; 216:355.</a></li><li><a class="nounderline abstract_t">Gkalpakiotis S, Arenberger P, Gkalpakioti P, et al. A case of acute generalized pustular psoriasis of von Zumbusch treated with adalimumab. J Eur Acad Dermatol Venereol 2015; 29:2063.</a></li><li><a class="nounderline abstract_t">Post H, Magnolo N, Böhm M. [Successful treatment of generalized pustular psoriasis with certolizumab]. Hautarzt 2021; 72:992.</a></li><li><a class="nounderline abstract_t">Skrabl-Baumgartner A, Weger W, Salmhofer W, Jahnel J. Childhood generalized pustular psoriasis: longtime remission with combined infliximab and methotrexate treatment. Pediatr Dermatol 2015; 32:e13.</a></li><li><a class="nounderline abstract_t">Gallo E, Llamas-Velasco M, Daudén E, García-Diez A. Refractory generalized pustular psoriasis responsive to a combination of adalimumab and acitretin. Int J Dermatol 2013; 52:1610.</a></li><li><a class="nounderline abstract_t">Kawakami H, Maeda T, Abe N, et al. Efficacy of adalimumab and methotrexate combination therapy on generalized pustular psoriasis patients unresponsive to infliximab monotherapy due to anti-infliximab antibody development. J Dermatol 2015; 42:94.</a></li><li><a class="nounderline abstract_t">Taguchi R, Takamura S, Teraki Y. Combination therapy with biologic and colchicine for generalized pustular psoriasis. Int J Dermatol 2020; 59:e400.</a></li><li><a class="nounderline abstract_t">Yu N, Li Y, Ding Y, Shi Y. Combination therapy with acitretin and glycyrrhizin in generalized pustular psoriasis with liver test abnormalities: A case series. Dermatol Ther 2020; 33:e13318.</a></li><li><a class="nounderline abstract_t">Kopp T, Karlhofer F, Szépfalusi Z, et al. Successful use of acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type. Br J Dermatol 2004; 151:912.</a></li><li><a class="nounderline abstract_t">Kim HS, Kim GM, Kim SY. Two-stage therapy for childhood generalized pustular psoriasis: low-dose cyclosporin for induction and maintenance with acitretin/narrowband ultraviolet B phototherapy. Pediatr Dermatol 2006; 23:306.</a></li><li><a class="nounderline abstract_t">Bachelez H, Choon SE, Marrakchi S, et al. Trial of Spesolimab for Generalized Pustular Psoriasis. N Engl J Med 2021; 385:2431.</a></li><li><a class="nounderline abstract_t">Suzuki A, Haruna K, Mizuno Y, et al. Successful treatment of three cases of generalized pustular psoriasis with granulocyte and monocyte adsorption apheresis. Ther Apher Dial 2012; 16:445.</a></li><li><a class="nounderline abstract_t">Fujisawa T, Moriya C, Shibuya Y, et al. Combination therapy of infliximab and granulocyte/monocyte adsorption apheresis for refractory pustular psoriasis with psoriatic arthritis. Acta Derm Venereol 2013; 93:364.</a></li><li><a class="nounderline abstract_t">Furusawa K, Hasegawa T, Ikeda S. Immunosuppressant and infliximab-resistant generalized pustular psoriasis successfully treated with granulocyte and monocyte adsorption apheresis. Ther Apher Dial 2012; 16:379.</a></li><li><a class="nounderline abstract_t">Ikeda S, Takahashi H, Suga Y, et al. Therapeutic depletion of myeloid lineage leukocytes in patients with generalized pustular psoriasis indicates a major role for neutrophils in the immunopathogenesis of psoriasis. J Am Acad Dermatol 2013; 68:609.</a></li><li><a class="nounderline abstract_t">Fujisawa T, Murase K, Okumura Y, et al. Generalized pustular psoriasis successfully treated with granulocyte and monocyte adsorption apheresis. Ther Apher Dial 2011; 15:374.</a></li><li><a class="nounderline abstract_t">Fujisawa T, Suzuki S, Mizutani Y, et al. Granulocyte and Monocyte Adsorption Apheresis for Generalized Pustular Psoriasis: Therapeutic Outcomes in Three Refractory Patients. Ther Apher Dial 2015; 19:336.</a></li><li><a class="nounderline abstract_t">Sugiura K, Haruna K, Suga Y, Akiyama M. Generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist successfully treated with granulocyte and monocyte adsorption apheresis. J Eur Acad Dermatol Venereol 2014; 28:1835.</a></li><li><a class="nounderline abstract_t">Tominaga C, Yamamoto M, Imai Y, Yamanishi K. A Case of Old Age-Onset Generalized Pustular Psoriasis with a Deficiency of IL-36RN (DITRA) Treated by Granulocyte and Monocyte Apheresis. Case Rep Dermatol 2015; 7:29.</a></li><li><a class="nounderline abstract_t">Viguier M, Guigue P, Pagès C, et al. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Intern Med 2010; 153:66.</a></li><li><a class="nounderline abstract_t">Hüffmeier U, Wätzold M, Mohr J, et al. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol 2014; 170:202.</a></li><li><a class="nounderline abstract_t">Skendros P, Papagoras C, Lefaki I, et al. Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition. Br J Dermatol 2017; 176:212.</a></li><li><a class="nounderline abstract_t">Ji YZ, Geng L, Ma XH, et al. Severe generalized pustular psoriasis treated with mycophenolate mofetil. J Dermatol 2011; 38:603.</a></li><li><a class="nounderline abstract_t">Verma S, Thakur BK. Dramatic response to oral zinc in a case of subacute form of generalized pustular psoriasis. Indian J Dermatol 2012; 57:323.</a></li><li><a class="nounderline abstract_t">Sheu JS, Divito SJ, Enamandram M, Merola JF. Dapsone Therapy for Pustular Psoriasis: Case Series and Review of the Literature. Dermatology 2016; 232:97.</a></li><li><a class="nounderline abstract_t">Jeon C, Nakamura M, Sekhon S, et al. Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities. JAAD Case Rep 2017; 3:495.</a></li><li><a class="nounderline abstract_t">Huang YW, Tsai TF. Pharmacological Management of Pediatric Pustular Psoriasis. Paediatr Drugs 2020; 22:265.</a></li><li><a class="nounderline abstract_t">Popadic S, Nikolic M. Pustular psoriasis in childhood and adolescence: a 20-year single-center experience. Pediatr Dermatol 2014; 31:575.</a></li><li><a class="nounderline abstract_t">Ergin S, Ersoy-Evans S, Sahin S, Ozkaya O. Acitretin is a safe treatment option for infantile pustular psoriasis. J Dermatolog Treat 2008; 19:341.</a></li><li><a class="nounderline abstract_t">Juanqin G, Zhiqiang C, Zijia H. Evaluation of the effectiveness of childhood generalized pustular psoriasis treatment in 30 cases. Pediatr Dermatol 1998; 15:144.</a></li><li><a class="nounderline abstract_t">Chen P, Li C, Xue R, et al. Efficacy and safety of acitretin monotherapy in children with pustular psoriasis: results from 15 cases and a literature review. J Dermatolog Treat 2018; 29:353.</a></li><li><a class="nounderline abstract_t">Yang H, Tan Q, Chen GH, et al. Plasma retinol as a predictive biomarker of disease activity and response to acitretin monotherapy in children with generalized pustular psoriasis. J Eur Acad Dermatol Venereol 2020; 34:e270.</a></li><li><a class="nounderline abstract_t">Alli N, Güngör E, Karakayali G, et al. The use of cyclosporin in a child with generalized pustular psoriasis. Br J Dermatol 1998; 139:754.</a></li><li><a class="nounderline abstract_t">Xiao T, Li B, He CD, Chen HD. Juvenile generalized pustular psoriasis. J Dermatol 2007; 34:573.</a></li><li><a class="nounderline abstract_t">Kiliç SS, Hacimustafaoğlu M, Celebi S, et al. Low dose cyclosporin A treatment in generalized pustular psoriasis. Pediatr Dermatol 2001; 18:246.</a></li><li><a class="nounderline abstract_t">Nakamura S, Hashimoto Y, Igawa S, et al. Childhood generalized pustular psoriasis treated by preprandial ciclosporin administration: serum cytokine pattern during the course of the disease. Clin Exp Dermatol 2009; 34:e1023.</a></li><li><a class="nounderline abstract_t">Dogra S, Mahajan R, Narang T, Handa S. Systemic cyclosporine treatment in severe childhood psoriasis: A retrospective chart review. J Dermatolog Treat 2017; 28:18.</a></li><li><a class="nounderline abstract_t">Garg T, Chander R, Mittal S. Familial juvenile generalized pustular psoriasis: response to methotrexate. Skinmed 2011; 9:190.</a></li><li><a class="nounderline abstract_t">Dogra S, Kumaran MS, Handa S, Kanwar AJ. Methotrexate for generalized pustular psoriasis in a 2-year-old child. Pediatr Dermatol 2005; 22:85.</a></li><li><a class="nounderline abstract_t">Pereira TM, Vieira AP, Fernandes JC, et al. Anti-TNF-alpha therapy in childhood pustular psoriasis. Dermatology 2006; 213:350.</a></li><li><a class="nounderline abstract_t">Fialová J, Vojáčková N, Vaňousová D, Hercogová J. Juvenile generalized pustular psoriasis treated with etanercept. Dermatol Ther 2014; 27:105.</a></li><li><a class="nounderline abstract_t">Cuperus E, Koevoets R, van der Smagt JJ, et al. Juvenile interleukin-36 receptor antagonist deficiency (DITRA) with c.80T&gt;C (p.Leu27Pro) mutation successfully treated with etanercept and acitretin. JAAD Case Rep 2018; 4:192.</a></li><li><a class="nounderline abstract_t">Tsang V, Dvorakova V, Enright F, et al. Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis. J Eur Acad Dermatol Venereol 2016; 30:e117.</a></li><li><a class="nounderline abstract_t">Hansel K, Marietti R, Tramontana M, et al. Childhood generalized pustular psoriasis: Successful long-term treatment with adalimumab. Dermatol Ther 2020; 33:e13294.</a></li><li><a class="nounderline abstract_t">Alvarez AC, Rodríguez-Nevado I, De Argila D, et al. Recalcitrant pustular psoriasis successfully treated with adalimumab. Pediatr Dermatol 2011; 28:195.</a></li><li><a class="nounderline abstract_t">Lu J, Li Y, Yu N, et al. Successful treatment of juvenile generalized pustular psoriasis with infliximab therapy: two case reports. J Int Med Res 2020; 48:300060520912091.</a></li><li><a class="nounderline abstract_t">Albela H, Begum S, Leong KF. Successful treatment of paediatric generalized pustular psoriasis with secukinumab: a case series. J Dermatolog Treat 2022; 33:1769.</a></li><li><a class="nounderline abstract_t">López-Sánchez C, Falla LM, Roé-Crespo E, et al. Excellent response to secukinumab in an infant with severe generalized pustular psoriasis. J Dermatol 2021; 48:907.</a></li><li><a class="nounderline abstract_t">Nishida M, Takeichi T, Kono M, et al. Successful secukinumab treatment of recalcitrant juvenile generalized pustular psoriasis. J Dermatol 2020; 47:e77.</a></li><li><a class="nounderline abstract_t">Georgesen C, Wildman H, Wang X, Magro C. Pediatric pustular psoriasis responsive to cyclosporine bridged to etanercept: A treatment approach. Dermatol Online J 2017; 23.</a></li><li><a class="nounderline abstract_t">Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358:241.</a></li><li><a class="nounderline abstract_t">Paller AS, Siegfried EC, Eichenfield LF, et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol 2010; 63:762.</a></li><li><a class="nounderline abstract_t">Paller AS, Siegfried EC, Pariser DM, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol 2016; 74:280.</a></li><li><a class="nounderline abstract_t">DiGiovanna JJ. Isotretinoin effects on bone. J Am Acad Dermatol 2001; 45:S176.</a></li><li><a class="nounderline abstract_t">Rossi-Semerano L, Piram M, Chiaverini C, et al. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Pediatrics 2013; 132:e1043.</a></li><li><a class="nounderline abstract_t">Chang L, Ubriani R, Yan AC. Picture of the month--quiz case. Pustular psoriasis, annular type. Arch Pediatr Adolesc Med 2008; 162:989.</a></li><li><a class="nounderline abstract_t">Bachelez H. Pustular psoriasis and related pustular skin diseases. Br J Dermatol 2018; 178:614.</a></li><li><a class="nounderline abstract_t">Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab. Br J Dermatol 2015; 173:239.</a></li><li><a class="nounderline abstract_t">Wilsmann-Theis D, Schnell LM, Ralser-Isselstein V, et al. Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations. J Dermatol 2018; 45:850.</a></li><li><a class="nounderline abstract_t">Zhu T, Jin H, Shu D, et al. Association of IL36RN mutations with clinical features, therapeutic response to acitretin, and frequency of recurrence in patients with generalized pustular psoriasis. Eur J Dermatol 2018; 28:217.</a></li><li><a class="nounderline abstract_t">Wang Y, Cheng R, Lu Z, et al. Clinical profiles of pediatric patients with GPP alone and with different IL36RN genotypes. J Dermatol Sci 2017; 85:235.</a></li><li><a class="nounderline abstract_t">Sehgal VN, Verma P, Sharma S, et al. Acrodermatitis continua of Hallopeau: evolution of treatment options. Int J Dermatol 2011; 50:1195.</a></li><li><a class="nounderline abstract_t">Pinard J, Vleugels RA, Kurtzman DJ, et al. Novel Application of High-Dose-Rate Brachytherapy for Severe, Recalcitrant Acrodermatitis Continua of Hallopeau. JAMA Dermatol 2017; 153:331.</a></li><li><a class="nounderline abstract_t">Sevrain M, Richard MA, Barnetche T, et al. Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion. J Eur Acad Dermatol Venereol 2014; 28 Suppl 5:13.</a></li><li><a class="nounderline abstract_t">Su LN, Ren J, Cheng SM, et al. UVA1 vs. narrowband UVB phototherapy in the treatment of palmoplantar pustulosis: a pilot randomized controlled study. Lasers Med Sci 2017; 32:1819.</a></li><li><a class="nounderline abstract_t">Di Costanzo L, Napolitano M, Patruno C, et al. Acrodermatitis continua of Hallopeau (ACH): two cases successfully treated with adalimumab. J Dermatolog Treat 2014; 25:489.</a></li><li><a class="nounderline abstract_t">Dini V, Barbanera S, Romanelli M. Efficacy of adalimumab for the treatment of refractory paediatric acrodermatitis continua of hallopeau. Acta Derm Venereol 2013; 93:588.</a></li><li><a class="nounderline abstract_t">Lutz V, Lipsker D. Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of hallopeau responsive to the interleukin 1 receptor antagonist anakinra. Arch Dermatol 2012; 148:297.</a></li><li><a class="nounderline abstract_t">Silpa-archa N, Wongpraparut C. A recalcitrant acrodermatitis continua of Hallopeau successfully treated with etanercept. J Med Assoc Thai 2011; 94:1154.</a></li><li><a class="nounderline abstract_t">Bertelsen T, Kragballe K, Johansen C, Iversen L. Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis. Int J Dermatol 2014; 53:e464.</a></li><li><a class="nounderline abstract_t">Jayasekera P, Parslew R, Al-Sharqi A. A case of tumour necrosis factor-α inhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab. Br J Dermatol 2014; 171:1546.</a></li><li><a class="nounderline abstract_t">Muggli D, Maul JT, Anzengruber F, et al. Secukinumab for Acrodermatitis Continua of Hallopeau. JAMA Dermatol 2017; 153:336.</a></li><li><a class="nounderline abstract_t">Baron JA. Acrodermatitis of Hallopeau and erosive oral mucositis successfully treated with secukinumab. JAAD Case Rep 2017; 3:215.</a></li><li><a class="nounderline abstract_t">Morales-Múnera C, Vilarrasa E, Puig L. Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis. Br J Dermatol 2013; 168:820.</a></li><li><a class="nounderline abstract_t">Buder V, Herberger K, Jacobi A, et al. Ustekinumab in the treatment of palmoplantar pustular psoriasis - a case series of nine patients. J Dtsch Dermatol Ges 2016; 14:1108.</a></li><li><a class="nounderline abstract_t">Adışen E, Özer İ, Temel B, Gürer MA. Ustekinumab for the treatment of acrodermatitis continua of Hallopeau refractory to anti-TNF agents. Dermatol Ther 2017; 30.</a></li><li><a class="nounderline abstract_t">Miller AC, Holland TE, Cohen DJ. Treatment of acrodermatitis continua of hallopeau with ixekizumab. J Dermatolog Treat 2021; 32:117.</a></li><li><a class="nounderline abstract_t">Milani-Nejad N, Kaffenberger J. Treatment of Recalcitrant Acrodermatitis Continua of Hallopeau With Brodalumab. J Drugs Dermatol 2019; 18:1047.</a></li><li><a class="nounderline abstract_t">Husson B, Barbe C, Hegazy S, et al. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol 2020; 34:2330.</a></li><li><a class="nounderline abstract_t">Saunier J, Debarbieux S, Jullien D, et al. Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra. Dermatology 2015; 230:97.</a></li><li><a class="nounderline abstract_t">Kromer C, Loewe E, Schaarschmidt ML, et al. Treatment of acrodermatitis continua of Hallopeau: A case series of 39 patients. J Dermatol 2020; 47:989.</a></li></ol></div><div id="topicVersionRevision">Topic 93554 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24491419" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Acute generalized pustular psoriasis, von Zumbusch type, treated in the burn unit. A review of clinical features and new therapeutics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10905601" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Recurrent cholestatic jaundice associated with generalized pustular psoriasis: evidence for a neutrophilic cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11122037" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Renal failure and cholestatic jaundice as unusual complications of childhood pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23967807" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11860564" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Annular pustular psoriasis--most common form of pustular psoriasis in children: report of three cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31813117" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Generalized Pustular Psoriasis: Clinical Management and Update on Autoinflammatory Aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31631466" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Successful management of infliximab-induced generalized pustular psoriasis without therapy discontinuation in a patient with psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31612467" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Biological therapy for pustular psoriasis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32615817" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Biologics in the treatment of pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31697211" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Review of treatments for generalized pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31486687" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : An update on generalized pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30230572" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10209919" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatments of generalized pustular psoriasis: a multicenter study in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1892402" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Generalized pustular psoriasis. A review of 63 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3862363" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17958816" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Childhood generalized pustular psoriasis: successful treatment with isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26437168" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Successful treatment of palmoplantar pustulosis with isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15088287" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24612941" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29386902" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19389524" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23575550" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The effect of folate supplementation on methotrexate efficacy and toxicity in psoriasis patients and folic acid use by dermatologists in the USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34116101" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22609220" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9431715" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Generalized pustular psoriasis responsive to PUVA and oral cyclosporin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23094312" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Generalized pustular psoriasis of Zambusch: case report of successful disease control with cyclosporine and etanercept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26046589" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Infant with generalized pustular psoriasis who responded to cyclosporin A therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12677432" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30672104" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Development of herpes zoster during infliximab treatment for pediatric generalized pustular psoriasis: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26704926" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: Results from the prospective post-marketing surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21752492" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-αinhibitors: the Mayo Clinic experience, 1998 to 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29484893" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Generalized Pustular Psoriasis Induced by Infliximab in a Patient With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23247492" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23680215" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Acute treatment of generalized pustular psoriasis of von Zumbusch with single-dose infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18086593" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Infliximab in recalcitrant generalized pustular arthropatic psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16774108" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Life-threatening pustular and erythrodermic psoriasis responding to infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16091999" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Successful treatment of Von Zumbusch pustular psoriasis with infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18974629" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and adalimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15149518" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14996114" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12873907" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Addition of low-dose methotrexate to infliximab in the treatment of a patient with severe, recalcitrant pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24910924" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Successful treatment with infliximab of sibling cases with generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25473247" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Two cases of generalized pustular psoriasis: successful treatment with infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23343611" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Rapid downregulation of innate immune cells, interleukin-12 and interleukin-23 in generalized pustular psoriasis with infliximab in combination with acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26919410" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26650014" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27231055" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Secukinumab in the Treatment of Generalized Pustular Psoriasis: A Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27760239" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Response to Interleukin (IL)-17 Inhibition in an Adolescent With Severe Manifestations of IL-36 Receptor Antagonist Deficiency (DITRA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28319281" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27981221" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Successful use of secukinumab in pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33237694" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Successful treatment of generalized pustular psoriasis with secukinumab: a report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33063316" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Generalized pustular psoriasis associated with systemic lupus erythematosus successfully treated with secukinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25355284" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27726163" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30746797" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Long-term efficacy of ixekizumab in erythrodermic and generalized pustular psoriasis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30317671" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31560979" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Real-world single-center experience with 10 cases of generalized pustular psoriasis successfully treated with ixekizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30998424" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A case of generalized pustular psoriasis and arthritis treated with ixekizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27106510" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20716216" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27096382" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28202422" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Clearance of annular pustular psoriasis with ustekinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27333948" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Generalized pustular psoriasis treated with ustekinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21254881" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Flare of pustular psoriasis after initiating ustekinumab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21233062" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29705819" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn's disease-associated spondyloarthropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24984757" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to adalimumab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29569397" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16427987" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Generalized pustular psoriasis of pregnancy treated with narrowband UVB and topical steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17297275" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Generalized pustular psoriasis and hepatic dysfunction associated with oral terbinafine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15787845" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Generalized pustular psoriasis successfully treated with topical tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19508565" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Generalized pustular psoriasis (von Zumbusch) following the use of calcipotriol and betamethasone dipropionate ointment: a report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17763600" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Subacute annular generalized pustular psoriasis treated with etanercept and cyclosporine combination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15564207" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Generalized pustular psoriasis (von Zumbusch) following iatrogenic hypocortisolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7928042" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Generalized pustular psoriasis precipitated by topical calcipotriol cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135156" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Generalized pustular psoriasis precipitated by topical calcipotriol ointment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22409471" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Generalized pustular psoriasis in a child: observation of long-term combination therapy with etretinate and calcipotriol for 16 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12975175" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A case of generalized pustular psoriasis treated with topical tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/911672" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Photochemotherapy for pustular psoriasis (von Zumbusch).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16428160" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18569276" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Long-term efficacy of adalimumab in generalized pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22506677" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Successful treatment with adalimumab in a patient with psoriatic arthritis and generalized pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22577283" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Etanercept in the treatment of generalized annular pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18285687" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Etanercept at different dosages in the treatment of generalized pustular psoriasis: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24981161" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A case of acute generalized pustular psoriasis of von Zumbusch treated with adalimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33687481" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : [Successful treatment of generalized pustular psoriasis with certolizumab].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25644044" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Childhood generalized pustular psoriasis: longtime remission with combined infliximab and methotrexate treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22834488" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Refractory generalized pustular psoriasis responsive to a combination of adalimumab and acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25425479" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Efficacy of adalimumab and methotrexate combination therapy on generalized pustular psoriasis patients unresponsive to infliximab monotherapy due to anti-infliximab antibody development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32492187" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Combination therapy with biologic and colchicine for generalized pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32182382" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Combination therapy with acitretin and glycyrrhizin in generalized pustular psoriasis with liver test abnormalities: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15491438" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Successful use of acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16780493" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Two-stage therapy for childhood generalized pustular psoriasis: low-dose cyclosporin for induction and maintenance with acitretin/narrowband ultraviolet B phototherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34936739" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Trial of Spesolimab for Generalized Pustular Psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23046369" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Successful treatment of three cases of generalized pustular psoriasis with granulocyte and monocyte adsorption apheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23007291" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Combination therapy of infliximab and granulocyte/monocyte adsorption apheresis for refractory pustular psoriasis with psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22817129" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Immunosuppressant and infliximab-resistant generalized pustular psoriasis successfully treated with granulocyte and monocyte adsorption apheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23332516" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Therapeutic depletion of myeloid lineage leukocytes in patients with generalized pustular psoriasis indicates a major role for neutrophils in the immunopathogenesis of psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21884472" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Generalized pustular psoriasis successfully treated with granulocyte and monocyte adsorption apheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26386221" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Granulocyte and Monocyte Adsorption Apheresis for Generalized Pustular Psoriasis: Therapeutic Outcomes in Three Refractory Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24490830" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist successfully treated with granulocyte and monocyte adsorption apheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25848350" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : A Case of Old Age-Onset Generalized Pustular Psoriasis with a Deficiency of IL-36RN (DITRA) Treated by Granulocyte and Monocyte Apheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20621920" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23909475" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27105586" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Successful response in a case of severe pustular psoriasis after interleukin-1βinhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21352286" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Severe generalized pustular psoriasis treated with mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22837577" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Dramatic response to oral zinc in a case of subacute form of generalized pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26465742" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Dapsone Therapy for Pustular Psoriasis: Case Series and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29034298" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32020425" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Pharmacological Management of Pediatric Pustular Psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24602000" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Pustular psoriasis in childhood and adolescence: a 20-year single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18608713" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Acitretin is a safe treatment option for infantile pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9572705" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Evaluation of the effectiveness of childhood generalized pustular psoriasis treatment in 30 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29098909" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Efficacy and safety of acitretin monotherapy in children with pustular psoriasis: results from 15 cases and a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31991497" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Plasma retinol as a predictive biomarker of disease activity and response to acitretin monotherapy in children with generalized pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9892934" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : The use of cyclosporin in a child with generalized pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17683391" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Juvenile generalized pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11438009" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Low dose cyclosporin A treatment in generalized pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20055828" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Childhood generalized pustular psoriasis treated by preprandial ciclosporin administration: serum cytokine pattern during the course of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27771982" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Systemic cyclosporine treatment in severe childhood psoriasis: A retrospective chart review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21675502" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Familial juvenile generalized pustular psoriasis: response to methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15660909" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Methotrexate for generalized pustular psoriasis in a 2-year-old child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17135745" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Anti-TNF-alpha therapy in childhood pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24703268" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Juvenile generalized pustular psoriasis treated with etanercept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29892664" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Juvenile interleukin-36 receptor antagonist deficiency (DITRA) with c.80T&gt;C (p.Leu27Pro) mutation successfully treated with etanercept and acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26403378" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32134546" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Childhood generalized pustular psoriasis: Successful long-term treatment with adalimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21504452" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Recalcitrant pustular psoriasis successfully treated with adalimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32216562" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Successful treatment of juvenile generalized pustular psoriasis with infliximab therapy: two case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33706651" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Successful treatment of paediatric generalized pustular psoriasis with secukinumab: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33543522" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Excellent response to secukinumab in an infant with severe generalized pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31907962" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Successful secukinumab treatment of recalcitrant juvenile generalized pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29447638" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Pediatric pustular psoriasis responsive to cyclosporine bridged to etanercept: A treatment approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18199863" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Etanercept treatment for children and adolescents with plaque psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20605256" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Long-term etanercept in pediatric patients with plaque psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26775775" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11606950" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Isotretinoin effects on bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24019411" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18838653" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Picture of the month--quiz case. Pustular psoriasis, annular type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29333670" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Pustular psoriasis and related pustular skin diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25495649" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Treatment of two patients with generalized pustular psoriasis with the interleukin-1βinhibitor gevokizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29655177" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29619998" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Association of IL36RN mutations with clinical features, therapeutic response to acitretin, and frequency of recurrence in patients with generalized pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28063630" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Clinical profiles of pediatric patients with GPP alone and with different IL36RN genotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21950286" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Acrodermatitis continua of Hallopeau: evolution of treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28122079" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Novel Application of High-Dose-Rate Brachytherapy for Severe, Recalcitrant Acrodermatitis Continua of Hallopeau.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24985558" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28699044" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : UVA1 vs. narrowband UVB phototherapy in the treatment of palmoplantar pustulosis: a pilot randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24215490" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Acrodermatitis continua of Hallopeau (ACH): two cases successfully treated with adalimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23407925" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Efficacy of adalimumab for the treatment of refractory paediatric acrodermatitis continua of hallopeau.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431771" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of hallopeau responsive to the interleukin 1 receptor antagonist anakinra.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21970208" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : A recalcitrant acrodermatitis continua of Hallopeau successfully treated with etanercept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24962808" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24890762" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : A case of tumour necrosis factor-αinhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28122071" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Secukinumab for Acrodermatitis Continua of Hallopeau.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28443313" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Acrodermatitis of Hallopeau and erosive oral mucositis successfully treated with secukinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23210683" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27879067" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Ustekinumab in the treatment of palmoplantar pustular psoriasis - a case series of nine patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28139054" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Ustekinumab for the treatment of acrodermatitis continua of Hallopeau refractory to anti-TNF agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31184530" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Treatment of acrodermatitis continua of hallopeau with ixekizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31603633" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Treatment of Recalcitrant Acrodermatitis Continua of Hallopeau With Brodalumab</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32030802" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25471551" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32632983" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Treatment of acrodermatitis continua of Hallopeau: A case series of 39 patients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
